Vascular Interventional Articles & Analysis
29 news found
For hard tissues, it mainly includes neurosurgery and orthopedic surgery robots; for soft tissues, it can be divided into lumpectomy surgery robots, transnatural cavity surgery robots, vascular intervention surgery robots and percutaneous puncture surgery robots.Surgical robots have high technical threshold and complex operation, and it is a long-term process ...
Arteriovenous malformations (AVMs) occur when capillaries, veins, and arteries don’t develop properly and may lead to cutaneous discoloration, sensitivity, pain, and vascular bleeding. Vascular embolization, performed by interventional radiologists, is an effective therapy for addressing the symptoms of patients suffering from this ...
Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced two publications that evaluated the Embrace™ Hydrogel Embolic System (HES) in preclinical porcine hemorrhage models. In a Journal of Vascular and Interventional Radiology (JVIR) publication, Dr. ...
This is the first step towards obtaining approval from China’s National Medical Products Administration (NMPA) for the commercialization of R-One™, its robotic solution for PCI (Percutaneous Coronary Intervention) in the Chinese market, where this is the first clinical study conducted on this scale in the field of vascular robotics. ...
ByRobocath
Aliso Viejo, CA – June 7, 2022 – Okami Medical Inc., a medical device company focused on developing innovative solutions that address key unmet clinical needs in peripheral vascular intervention, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the LOBO-7 and LOBO-9 Vascular Occluders, the latest addition to ...
Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced the publication of results[i] from the first-in-human clinical trial of Embrace™ Hydrogel Embolic System (HES) for the treatment of hypervascular tumors, in the Journal of Vascular and Interventional ...
Confluent provides a broad range of capabilities including developing and manufacturing components, delivery systems and finished devices for medical device OEMs in many of the fastest growing healthcare subsectors, including neurovascular, structural heart, electrophysiology, aortic intervention, peripheral vascular and ENT. Confluent is a strategic partner to a ...
The procedure took place at the 301 Hospital in Beijing on November 24; performed by Dr. Yundai Chen, a renowned interventional cardiologist and author of several scientific publications. ...
ByRobocath
Q’Apel Medical, Inc., an innovative neurovascular company specializing in developing and commercializing novel access device technology for vascular interventions, announced today the launch of the Armadillo Radial Access System, the latest application of the SelectFlex™ technology and part of the SelectFlex™ Family of Neurovascular access ...
Initiating our U.S Food and Drug Administration (FDA) C-Guardians IDE trial this quarter marked a milestone for the company in establishing awareness and experience with CGuard EPS among U.S. physicians treating carotid artery disease. To date, Interventional Cardiologist Chris Metzger, M.D., our principal investigator, and system chair of clinical research at Ballad Health ...
Q’Apel Medical, Inc., an innovative neurovascular company specializing in developing and commercializing novel access device technology for vascular interventions, is pleased to announce and welcome Thomas Berryman as Chief Financial Officer. ...
The main products we provide cover many fields such as minimally invasive tumor intervention, vascular intervention, radiotherapy, radiology and ultrasound diagnosis, surgical operation and interventional consumables, orthopedic rehabilitation consumables. ...
ByRTsafe
New 35,000 square foot Facility will support the company’s growth and OUS expansion Q’Apel Medical, Inc., an innovative neurovascular company specializing in developing and commercializing novel access device technology for vascular interventions, announced today that it will relocate its existing headquarters into a new building at 4245 Technology ...
The proceeds from the Series D financing will also be used to advance Truvic’s development and commercialization of novel technologies for the treatment of peripheral vascular disease. “We are grateful for the confidence our investors have placed in us through this major financing, which we believe will have a profound impact on our ability to accelerate development ...
Q’Apel Medical, Inc., an innovative neurovascular company specializing in developing and commercializing novel access device technology for vascular interventions, is pleased to announce and welcome Jodie Fam as Vice President and General Manager, International. ...
Q’Apel Medical, Inc., an innovative neurovascular company specializing in developing and commercializing novel access device technology for vascular interventions, announced today it has raised $22 Million in Series C funding. ...
Nonetheless, I’m convinced that the future of interventional cardiology is robotic and that this remote connection module will speed up growth in this ...
ByRobocath
Bluegrass Vascular Technologies (Bluegrass Vascular), a private medical technology company focused on innovating lifesaving devices and methods for vascular access procedures, announced today the publication of the results from the company’s prospective, multicenter SAVE (Surfacer® System to Facilitate Access in VEnous Occlusions) ...
Bret Wiechmann and his team at Vascular and Interventional Physicians in Gainesville, FL implanted the first commercial BioMimics 3D Vascular stent in the US, on the same day that the device was officially launched in the US. ...
In preparation for this important commercial step, we have recruited a senior sales team, highly experienced in percutaneous vascular intervention, led by Joe DeJohn, Veryan’s US-based, Chief Commercial Officer. ...